Biogen (BIIB) Asset Writedowns and Impairment (2009 - 2026)

Biogen has reported Asset Writedowns and Impairment for 11 years, with the latest figure at $4.8 million in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 34.25% year-over-year to $4.8 million in Q1 2026; TTM through Jun 2026 was $57.7 million, a 10.12% decrease from a year earlier, with the FY2025 full-year figure at $52.9 million, down 48.09% from the prior year.
• Asset Writedowns and Impairment was $4.8 million for Q1 2026 at Biogen, down from $52.9 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $281.5 million in Q1 2022, with the low at $3.5 million in Q2 2025.
• Average Asset Writedowns and Impairment over 5 years is $96.8 million, with a median of $30.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment soared 1733.33% in 2022, then tumbled 93.82% in 2023.
• Over 5 years, Asset Writedowns and Impairment stood at $275.0 million in 2022, then plunged by 77.35% to $62.3 million in 2023, then sank by 46.71% to $33.2 million in 2024, then surged by 59.34% to $52.9 million in 2025, then slumped by 90.93% to $4.8 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $4.8 million (Q1 2026), $52.9 million (Q4 2025), and $3.5 million (Q2 2025), per Business Quant data.